Table 1.

Karyotypes and Kinase domain (KD) mutations during the course of the disease. Correlation between karyotypes and KD mutations in order to monitor the cytogenetic and molecular changes.

Months	Karyotypes	BCR–ABL1 Kinase Domain mutation
At diagnosis (October 2010)	46,XY,t(9;22)(q34;q11), [20 metaphases]	native BCR–ABL1
3 months (January 2011)	46,XY,t(9;11;22)(q34;p15;q11), [20 metaphases]	low- level mutation: E255V and E258V
5 months (March 2011)	46,XY [49 metaphases]/46,XY,t(9;22)(q34;q11), [23 metaphases]	native BCR–ABL1
8 months (June 2011)	49,XY,t(9;11;22)(q34;p15;q11),+6,+9,+der(22) t(9;22), [20 metaphases]	low- level mutation: E255V and E258V
9 months- 24 months (July 2011–October 2012) after BMT	46,XX, [20 metaphases]	BCR–ABL1 not present
25 months (November 2012)	47,XY,t(9;11;22)(q34;p15;q11),+der(22). [20 metaphases]	increase of level mutation E255V and E258V